文献速递主动脉疾病

编辑精选——短颈、近肾及肾上主动脉瘤初次开窗腔内修复术的单中心中期经验

Editor's Choice - Single Centre Midterm Experience with Primary Fenestrated Endovascular Aortic Aneurysm Repair for Short Neck, Juxtarenal, and Suprarenal Aneurysms.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2023-02-25

该单中心研究纳入2010年1月至2020年5月间接受初次开窗腔内主动脉修复术(FEVAR)治疗短颈、近肾或肾上主动脉瘤的349例患者,报告围手术期及五年中期结局。技术成功率98%(342/349),30天死亡率0.9%(3/349),五年估计生存率69.3±3.1%,动脉瘤相关死亡免除率98.8%±0.7%。作者结论认为FEVAR中期结果良好,但相当比例患者需要再干预,再干预对中期生存无负面影响。

要点

  • 349例短颈、近肾或肾上主动脉瘤患者接受初次FEVAR,技术成功率98%(342/349)。
  • 30天死亡率为0.9%(3/349),五年动脉瘤相关死亡免除率为98.8%±0.7%。
  • 五年估计靶血管通畅率98.7±0.4%,再干预免除率86.5±2.3%。

核心结论

  • FEVAR中期结果仍然良好,表现为持续的靶血管通畅率和较低的主动脉相关死亡率。
  • 相当比例患者需要再干预,但再干预对中期生存无负面影响。

研究设计与样本

  • 单中心研究,纳入2010年1月至2020年5月期间接受初次开窗腔内主动脉修复术(FEVAR)治疗短颈、近肾或肾上主动脉瘤并在该中心随访的患者。
  • 共纳入349例患者(313例男性,平均年龄72.3±7.7岁)。
  • 分析早期结局(技术成功、手术死亡、脊髓缺血)和五年结局(累积生存、主动脉相关死亡免除、靶血管通畅、靶血管不稳定[target vessel instability, TVI]、再干预)。

主要发现

  • 技术成功率为98%(342/349)。
  • 30天死亡率为0.9%(3/349)。
  • 五年估计生存率为69.3±3.1%。
  • 五年动脉瘤相关死亡免除率为98.8%±0.7%。
  • 五年估计靶血管通畅率为98.7±0.4%。

关键数值与推荐

  • 五年估计TVI免除率为97.2±0.6%。
  • 五年估计再干预免除率为86.5±2.3%。
  • 有再干预与无再干预患者的生存差异无统计学显著性(p = .088)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The use of fenestrated stent grafts to treat short neck, juxta- and suprarenal aortic aneurysms is increasing worldwide, but midterm outcome reports are scarce. This study aimed to report peri-operative results and midterm outcomes after five years from a single centre. METHODS: Patients treated with primary fenestrated endovascular aortic aneurysm repair (FEVAR) for short neck, juxta- or suprarenal aortic aneurysms within the period January 2010 to May 2020 with follow up in the centre were included. Early (technical success, operative mortality, spinal cord ischaemia) and five year outcomes (cumulative survival, freedom from aortic related death, target vessel patency, target vessel instability [TVI], re-interventions) were analysed. RESULTS: A total of 349 patients (313 male, mean age 72.3 ± 7.7 years) were included in the study. Technical success was 98% (342/349). The thirty day mortality rate was 0.9% (3/349). Estimated survival at five years was 69.3 ± 3.1%. Freedom from aneurysm related death at five years was 98.8% ± 0.7%. Estimated target vessel patency at five years was 98.7 ± 0.4%. Estimated freedom from TVI at five years was 97.2 ± 0.6%. Estimated freedom from re-intervention at five years was 86.5 ± 2.3%. Survival did not differ significantly between patients with and without re-interventions (p = .088). CONCLUSION: Midterm results of FEVAR remain good as indicated by sustained target vessel patency and low aortic related mortality rates. An important proportion of patients require re-interventions, which do not have a negative impact on midterm survival.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Katsargyris A, Marques de Marino P, Hasemaki N, et al. Editor's Choice - Single Centre Midterm Experience with Primary Fenestrated Endovascular Aortic Aneurysm Repair for Short Neck, Juxtarenal, and Suprarenal Aneurysms. Eur J Vasc Endovasc Surg. 2023. PMID: 36842460. doi:10.1016/j.ejvs.2023.02.069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。